SEC "Safe Harbor" statement rules restrict what companies can say or project about their share's present or future value.
Here's the Anavex Safe Harbor Statement:
Safe Harbor
This presentation contains forward-looking statements made within the meaning of the
Private Securities Litigation Reform Act of 1995 by Anavex™ Life Sciences Corp. and its
representatives. These statements can be identified by introductory words such as
"expects," "plans," "intends," "believes," "will," "estimates," "forecasts," '"projects" or
words of similar meaning, and by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements frequently are used in discussing potential
product applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters. Many factors
may cause actual results to differ from forward-looking statements, including inaccurate
assumptions and a broad variety of risks and uncertainties, some of which are known and
others of which are not. Known risks and uncertainties include those identified from time to
time in the reports filed by Anavex Life Sciences Corp. with the Securities and Exchange
Commission, which should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and one should avoid
placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no
obligation to update publicly any forward-looking statements, whether as a result of new
information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or
if it will be permitted by regulatory agencies to undertake clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the expected timing
of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp.
will obtain regulatory approval for any "phase" of clinical trials. We also cannot be sure of
the clinical outcome for efficacy or safety of our compounds. Potential investors should refer
to the risk factors in our reports filed on Edgar.
Consequently, astute retail investors must determine for themselves the validity and applicability of company-provided information and data.
Anavex had to use the phrase "seem to" when stating their clinical results. Truthfully (prohibited by the Safe Harbor law) the phrase should have been "do indicate."
Lawyers and legal lanquage "protect" us. Aren't we thankful?
AI
